| pubmed-article:20035424 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:20035424 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:20035424 | lifeskim:mentions | umls-concept:C0152013 | lld:lifeskim |
| pubmed-article:20035424 | lifeskim:mentions | umls-concept:C0206062 | lld:lifeskim |
| pubmed-article:20035424 | lifeskim:mentions | umls-concept:C1135135 | lld:lifeskim |
| pubmed-article:20035424 | lifeskim:mentions | umls-concept:C2347900 | lld:lifeskim |
| pubmed-article:20035424 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:20035424 | pubmed:dateCreated | 2010-1-20 | lld:pubmed |
| pubmed-article:20035424 | pubmed:abstractText | Small-molecule tyrosine kinase inhibitors (TKIs) targeting the epidermal growth factor receptor (EGFR) pathways are used clinically for patients with non-small cell lung cancer (NSCLC). It is well established that somatic mutations in the kinase domain of the EGFR (Lynch et al. in N Engl J Med 350:2129-2139, 2004; Paez et al. in Science 304:1497-1500, 2004) are strongly associated with the tumor response and clinical outcomes in patients with NSCLC receiving EGFR-TKIs (Mitsudomi and Yatabe in Cancer Sci 98:1817-1824, 2007). Although the most common adverse events are skin rash and diarrhea, the most serious adverse effect reported is drug-related interstitial lung disease (ILD) (Inoue et al. in Lancet 361:137-139, 2003; Ando et al. in J Clin Oncol 24:2549-2556, 2006). The precise mechanism underlying the development of drug-related ILD remains unknown. Here, we describe a case of EGFR-mutant NSCLC who was rechallenged with the small-molecule EGFR antagonist erlotinib after developing gefitinib-related ILD. | lld:pubmed |
| pubmed-article:20035424 | pubmed:language | eng | lld:pubmed |
| pubmed-article:20035424 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20035424 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:20035424 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20035424 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20035424 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20035424 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20035424 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:20035424 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:20035424 | pubmed:month | Mar | lld:pubmed |
| pubmed-article:20035424 | pubmed:issn | 1432-0843 | lld:pubmed |
| pubmed-article:20035424 | pubmed:author | pubmed-author:KubotaMasaruM | lld:pubmed |
| pubmed-article:20035424 | pubmed:author | pubmed-author:HataishiRyuji... | lld:pubmed |
| pubmed-article:20035424 | pubmed:author | pubmed-author:MitsufujiHisa... | lld:pubmed |
| pubmed-article:20035424 | pubmed:author | pubmed-author:JiangShi-XuSX | lld:pubmed |
| pubmed-article:20035424 | pubmed:author | pubmed-author:MasudaNoriyuk... | lld:pubmed |
| pubmed-article:20035424 | pubmed:author | pubmed-author:KatagiriMasat... | lld:pubmed |
| pubmed-article:20035424 | pubmed:author | pubmed-author:IgawaSatoshiS | lld:pubmed |
| pubmed-article:20035424 | pubmed:author | pubmed-author:FukuiTomoyaT | lld:pubmed |
| pubmed-article:20035424 | pubmed:author | pubmed-author:NishiiYasutoY | lld:pubmed |
| pubmed-article:20035424 | pubmed:author | pubmed-author:OtaniSakikoS | lld:pubmed |
| pubmed-article:20035424 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:20035424 | pubmed:volume | 65 | lld:pubmed |
| pubmed-article:20035424 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:20035424 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:20035424 | pubmed:pagination | 803-6 | lld:pubmed |
| pubmed-article:20035424 | pubmed:meshHeading | pubmed-meshheading:20035424... | lld:pubmed |
| pubmed-article:20035424 | pubmed:meshHeading | pubmed-meshheading:20035424... | lld:pubmed |
| pubmed-article:20035424 | pubmed:meshHeading | pubmed-meshheading:20035424... | lld:pubmed |
| pubmed-article:20035424 | pubmed:meshHeading | pubmed-meshheading:20035424... | lld:pubmed |
| pubmed-article:20035424 | pubmed:meshHeading | pubmed-meshheading:20035424... | lld:pubmed |
| pubmed-article:20035424 | pubmed:meshHeading | pubmed-meshheading:20035424... | lld:pubmed |
| pubmed-article:20035424 | pubmed:meshHeading | pubmed-meshheading:20035424... | lld:pubmed |
| pubmed-article:20035424 | pubmed:meshHeading | pubmed-meshheading:20035424... | lld:pubmed |
| pubmed-article:20035424 | pubmed:meshHeading | pubmed-meshheading:20035424... | lld:pubmed |
| pubmed-article:20035424 | pubmed:meshHeading | pubmed-meshheading:20035424... | lld:pubmed |
| pubmed-article:20035424 | pubmed:meshHeading | pubmed-meshheading:20035424... | lld:pubmed |
| pubmed-article:20035424 | pubmed:year | 2010 | lld:pubmed |
| pubmed-article:20035424 | pubmed:articleTitle | Successful rechallenge with erlotinib in a patient with EGFR-mutant lung adenocarcinoma who developed gefitinib-related interstitial lung disease. | lld:pubmed |
| pubmed-article:20035424 | pubmed:affiliation | Department of Respiratory Medicine, School of Medicine, Kitasato University, Kitasato 1-15-1, Sagamihara, Kanagawa 228-8555, Japan. tofukui@med.kitasato-u.ac.jp | lld:pubmed |
| pubmed-article:20035424 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:20035424 | pubmed:publicationType | Case Reports | lld:pubmed |
